Stockholm, February 16, 2022 - Intervacc AB (publ) announces that the Company’s application for a Permit for Sale and Distribution of Strangvac® in the U.S. has been submitted to the U.S. Department of ... Read more
Stockholm, February 1, 2022 - The European patent for Strangvac®, a vaccine against equine strangles, is approved and in force until May 2031. Pending the approval of the supplementary protection ... Read more
Stockholm, January 21, 2022 - In the largest study of its kind, published in the 'Equine Veterinary Journal', scientists confirm that the antigens used in the Strangvac vaccine were highly conserved regardless of which ... Read more
Stockholm, December 17, 2021 - Due to the large and volatile trading in the company's share based on speculations on social media, Intervacc wants to clarify that Strangvac is centrally approved by EMA for sales ... Read more
Stockholm, December 15, 2021 - Nasdaq Stockholm has decided to temporarily stop trading in Intervacc after a volatile trading session and a decline in the share price. The reason for the price decline is speculation in ... Read more
Stockholm, December 14, 2021 - Intervacc AB (“Intervacc”) announces today that sales of the company’s Strangles vaccine Strangvac are planned to begin in the first quarter of 2022.
Intervacc's ... Read more